A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer
This page documents how this source is reused across Claim by Claim. A source can support, challenge, qualify or contextualize different claims; appearing here does not imply endorsement of every linked proposition.
Evidence roles describe what this source helps establish inside each Investigation. They are local to that use, not permanent labels attached to the publication itself.
The phase II pancreatic study randomized 36 people (34 treated); ascorbate plus chemotherapy showed median OS 16.0 vs 8.3 months, HR 0.46 with a 90% (not 95%) CI 0.23–0.92. The trial is small and adjunctive, not evidence of vitamin C alone curing cancer.